JP2021506800A5 - - Google Patents
Info
- Publication number
- JP2021506800A5 JP2021506800A5 JP2020532689A JP2020532689A JP2021506800A5 JP 2021506800 A5 JP2021506800 A5 JP 2021506800A5 JP 2020532689 A JP2020532689 A JP 2020532689A JP 2020532689 A JP2020532689 A JP 2020532689A JP 2021506800 A5 JP2021506800 A5 JP 2021506800A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- bfl
- disease
- sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023120833A JP2023129587A (ja) | 2017-12-15 | 2023-07-25 | 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化 |
| JP2026019183A JP2026086637A (ja) | 2017-12-15 | 2026-02-09 | 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762599229P | 2017-12-15 | 2017-12-15 | |
| US62/599,229 | 2017-12-15 | ||
| PCT/US2018/065438 WO2019118719A1 (en) | 2017-12-15 | 2018-12-13 | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120833A Division JP2023129587A (ja) | 2017-12-15 | 2023-07-25 | 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021506800A JP2021506800A (ja) | 2021-02-22 |
| JP2021506800A5 true JP2021506800A5 (enExample) | 2022-02-28 |
| JP7575944B2 JP7575944B2 (ja) | 2024-10-30 |
Family
ID=65276261
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020532689A Active JP7575944B2 (ja) | 2017-12-15 | 2018-12-13 | 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化 |
| JP2023120833A Pending JP2023129587A (ja) | 2017-12-15 | 2023-07-25 | 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化 |
| JP2026019183A Pending JP2026086637A (ja) | 2017-12-15 | 2026-02-09 | 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023120833A Pending JP2023129587A (ja) | 2017-12-15 | 2023-07-25 | 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化 |
| JP2026019183A Pending JP2026086637A (ja) | 2017-12-15 | 2026-02-09 | 構造安定化および／またはシステイン反応性ｎｏｘａペプチドによるアポトーシスタンパク質の選択的標的化 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11834520B2 (enExample) |
| EP (1) | EP3737404A1 (enExample) |
| JP (3) | JP7575944B2 (enExample) |
| AU (1) | AU2018383633B2 (enExample) |
| CA (1) | CA3079758A1 (enExample) |
| WO (1) | WO2019118719A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7049989B2 (ja) | 2015-08-28 | 2022-04-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｂｆｌ－１と結合するペプチド |
| US20190002506A1 (en) | 2015-08-28 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Stabilized peptides for covalent binding to target protein |
| WO2019118719A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides |
| WO2025155817A1 (en) * | 2024-01-17 | 2025-07-24 | Regents Of The University Of Minnesota | Lymphocytes including altered noxa activity |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| ES2211033T3 (es) | 1998-01-07 | 2004-07-01 | Debio Recherche Pharmaceutique S.A. | Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos. |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| BR0001870B1 (pt) | 2000-05-29 | 2014-02-25 | Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas | |
| US20040093164A1 (en) | 2002-11-08 | 2004-05-13 | Carlson William D. | Computer system and methods for producing morphogen analogs of human TDF-1 |
| EP1680443B9 (en) | 2003-11-05 | 2014-09-03 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
| EP1718748A1 (en) | 2004-02-06 | 2006-11-08 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic molecules and methods for generating and/or selecting same |
| EP1910535B1 (en) | 2005-06-24 | 2016-08-17 | The Walter And Eliza Hall Institute Of Medical Research | Therapeutic pro-apoptotic bh3-like molecules and methods for generating and/or selecting the same |
| US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
| EP2208061B1 (en) | 2007-09-26 | 2017-11-08 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| JP5788178B2 (ja) | 2008-01-23 | 2015-09-30 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | ウィルス感染症の治療のための組成物及び方法 |
| WO2010060112A1 (en) | 2008-11-24 | 2010-05-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with improved properties |
| EP3549951A3 (en) | 2008-12-09 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of mcl-1 |
| EP3698811A1 (en) | 2009-06-18 | 2020-08-26 | Dana Farber Cancer Institute, Inc. | Structured viral peptide compositions and methods of use |
| WO2013102211A2 (en) | 2011-12-29 | 2013-07-04 | Walensky Loren D | Stabilized antiviral fusion helices |
| BR112014016744A2 (en) | 2012-01-06 | 2018-09-04 | Complix Nv | polypeptide, pharmaceutical composition and method for producing one or more polypeptides |
| WO2013116829A1 (en) | 2012-02-03 | 2013-08-08 | The Trustees Of Princeton University | Novel engineered potent cytotoxic stapled bh3 peptides |
| AU2013235425B2 (en) | 2012-03-20 | 2017-09-21 | Dana Farber Cancer Institute, Inc. | Inhibition of MCL-1 and/or BFL-1/A1 |
| US9493510B2 (en) | 2013-01-10 | 2016-11-15 | Noliva Therapeutics Llc | Peptidomimetic compounds |
| WO2014151369A2 (en) | 2013-03-15 | 2014-09-25 | Dana-Farber Cancer Institute, Inc. | Stabilized ezh2 peptides |
| US20190002506A1 (en) | 2015-08-28 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Stabilized peptides for covalent binding to target protein |
| JP7049989B2 (ja) | 2015-08-28 | 2022-04-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｂｆｌ－１と結合するペプチド |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| WO2019118719A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive noxa peptides |
-
2018
- 2018-12-13 WO PCT/US2018/065438 patent/WO2019118719A1/en not_active Ceased
- 2018-12-13 AU AU2018383633A patent/AU2018383633B2/en active Active
- 2018-12-13 EP EP18842760.3A patent/EP3737404A1/en active Pending
- 2018-12-13 JP JP2020532689A patent/JP7575944B2/ja active Active
- 2018-12-13 US US16/766,201 patent/US11834520B2/en active Active
- 2018-12-13 CA CA3079758A patent/CA3079758A1/en active Pending
-
2023
- 2023-07-25 JP JP2023120833A patent/JP2023129587A/ja active Pending
- 2023-10-25 US US18/494,623 patent/US12466853B2/en active Active
-
2025
- 2025-10-09 US US19/354,527 patent/US20260226104A1/en active Pending
-
2026
- 2026-02-09 JP JP2026019183A patent/JP2026086637A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ratner et al. | A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor | |
| CN116036278B (zh) | 用于治疗具有非典型braf突变的癌症的组合物和方法 | |
| Rahal et al. | Genomics of adult and pediatric solid tumors | |
| ES2444695T3 (es) | Polinucleótidos y polipéptidos implicados en el cáncer | |
| Shangary et al. | Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family | |
| JP2021521155A5 (enExample) | ||
| Mumert et al. | Functional genomics identifies drivers of medulloblastoma dissemination | |
| JP2018534296A5 (enExample) | ||
| Macheleidt et al. | Preclinical studies reveal that LSD 1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations | |
| Liu et al. | CRISPR/Cas9‑mediated hypoxia inducible factor‑1α knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma | |
| JP2017513826A5 (enExample) | ||
| AU2023286673A1 (en) | Formulations for modulating myc expression | |
| JP2016224056A5 (enExample) | ||
| Fahrenkrog | Nucleoporin gene fusions and hematopoietic malignancies | |
| JP2025503971A5 (enExample) | ||
| EP3513192A1 (en) | Cell death biomarker | |
| CN104519898A (zh) | 用于治疗癌症的方法和药物组合物 | |
| Rásó | Splice variants of RAS—translational significance | |
| MX2012011668A (es) | Peptidos cdca5 y vacunas que incluyen los mismos. | |
| Amaral et al. | Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia: ACUTE LYMPHOBLASTIC LEUKEMIA | |
| JP2022511881A5 (enExample) | ||
| Kim et al. | TP53 mutation status in myelodysplastic neoplasm and acute myeloid leukemia: impact of reclassification based on the 5th WHO and International Consensus Classification criteria: a Korean multicenter study | |
| US20240067684A1 (en) | Constitutively active payloads | |
| Salek-Ardakani et al. | 1123 Preclinical activity and safety profile or JANX008, a novel EGFR-targeting tumor-activated T cell engager for treatment of solid tumors | |
| CN114846156A (zh) | Hla-h、hla-j、hla-l、hla-v和hla-y作为治疗和诊断靶 |